News

Unrecognized MI common with impaired fasting glucose


 

AT THE AHA SCIENTIFIC SESSIONS

References

CHICAGO– Impaired fasting glucose was associated with a doubled risk of asymptomatic or unrecognized myocardial infarction during prospective follow-up of subjects without overt cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis.

The clinical relevance of this finding lies in previous work establishing that asymptomatic, unrecognized MIs are associated with a prognosis as serious as for symptomatic MIs.

“Because of the high prevalence of impaired fasting glucose, the implications of this finding may have ramifications for a large proportion of the adult population,” Dr. Richard B. Stacey observed at the American Heart Association Scientific Sessions.

The magnitude of the risk of unrecognized MI was associated with duration of exposure to abnormal blood glucose levels in the landmark population-based MESA study. Subjects with impaired fasting glucose (IFG) noted on at least three of five biannual examinations conducted over a 10-year period had an adjusted 1.97-fold greater risk of experiencing an unrecognized MI during that time, compared with MESA participants who had normal blood glucose, added Dr. Stacey of Wake Forest University in Winston-Salem, N.C.

He presented two new analyses from the MESA study. One was cross-sectional: Among 4,955 study participants with normal fasting glucose and 930 with IFG upon study enrollment, a baseline 12-lead ECG revealed a prior unrecognized MI in 1.4% of those with normal fasting glucose and 3.2% of those with IFG, a 2.3-fold increase. MESA participants were on average in their mid-60s, and none had clinical cardiovascular disease.

In a multivariate logistic regression analysis fully adjusted for demographics and the standard cardiovascular risk factors as well as body mass index and the use of antihypertensive and lipid-lowering medications, IFG was associated with a 1.63-fold increased risk of prior asymptomatic or unrecognized MI (P < .001).

The other, prospective, longitudinal analysis, included 872 subjects with baseline normal fasting glucose and 545 with IFG, none of whom had evidence of a prior unrecognized MI at entry. This analysis excluded individuals who developed diabetes mellitus, had a clinically recognized MI, or underwent coronary revascularization during follow-up. During 10 years of follow-up, 14.9% of the group who continued to have normal fasting glucose experienced an unrecognized MI, as did 23.8% of those with IFG at entry. The unrecognized MIs were detected either by the presence of pathologic Q waves or minor Q waves with ST-T abnormalities on ECG or by an MRI showing late gadolinium enhancement indicative of myocardial scar.

The MESA study is funded by the National Institutes of Health. Dr. Stacey reported having no financial conflicts.

bjancin@frontlinemedcom.com

Recommended Reading

No difference between losartan and atenolol treatments for aortic-root dilation
MDedge Family Medicine
VIDEO: Study reignites dental antibiotic prophylaxis controversy
MDedge Family Medicine
VIDEO: Bioabsorbable polymer stents offer improved deliverability
MDedge Family Medicine
Heart attack survival better with basic vs. advanced life support
MDedge Family Medicine
Oxygen may make STEMI worse
MDedge Family Medicine
Pushing LDL below 25 mg/dL with alirocumab safe ‘so far’
MDedge Family Medicine
Prehospital epinephrine tied to lower neurologically intact survival
MDedge Family Medicine
Few receive evidence-based counseling about sex after myocardial infarction
MDedge Family Medicine
Takotsubo cardiomyopathy: predicting in-hospital mortality
MDedge Family Medicine
Key definitions, data standards established for CV endpoints
MDedge Family Medicine